Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines

NCT07013279 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 324

Last updated 2025-06-10

No results posted yet for this study

Summary

To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines

Conditions

  • Glabellar Lines

Interventions

BIOLOGICAL

DWP712 inj.

Clostridium botulinum Toxin

BIOLOGICAL

Botox® 100 Units

Clostridium botulinum Toxin

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2025-12-31
Completion
2026-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07013279 on ClinicalTrials.gov